Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

Register of interests (PDF 152 KB)

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Final draft guidance

Final appraisal document (PDF 241 KB)

Committee papers (PDF 8.94 MB)

Public committee slides ACM1 - clinical effectiveness (PDF 888 KB)

Public committee slides ACM1 - cost effectiveness (PDF 335 KB)

Public committee slides ACM2 (PDF 546 KB)

Final scope (PDF 252 KB)

Final matrix (PDF 264 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 286 KB)